Regeneron Pharmaceuticals Inc's market capitalization of $70,174,520,546 is ahead of 97.61% of US-listed equities.
REGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,143.41 -- higher than 98.05% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for Regeneron Pharmaceuticals Inc is higher than 88.23% of stocks in our set with a positive cash flow.
Stocks with similar financial metrics, market capitalization, and price volatility to Regeneron Pharmaceuticals Inc are AMD, VRTX, MU, AMAT, and NTES.
REGN's SEC filings can be seen here. And to visit Regeneron Pharmaceuticals Inc's official web site, go to www.regeneron.com.
Regeneron Pharmaceuticals, Inc. (REGN) Company Bio
Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.
REGN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Regeneron Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 34th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 43.17%. The most interesting components of our discounted cash flow analysis for Regeneron Pharmaceuticals Inc ended up being:
Interest coverage, a measure of earnings relative to interest payments, is 90.22 -- which is good for besting 94.47% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 5.2% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 55.41% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as REGN, try JNJ, PDEX, PRAH, GSK, and XRAY.
The S&P 500 Index is a market-capitalization-weighted index of the 500 largest publicly traded companies in the U.S. It is widely regarded as the best gauge of large-cap U.S. equities. Some of the largest companies in the index include Microsoft Corp.
Regeneron Pharmaceuticals recently made a significant upside breakout. Pretty amazing for a stock that has more than doubled in the past 12 months. Let's go over our charts and indicators so we can show you what we mean.